Should BTKi therapy be discontinued in CLL

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=EARIjyUOwZM

Kerry Rogers, MD, Ohio State University, Columbus, OH, advocates for the continuous use of BTK inhibitors (BTKis) in chronic lymphocytic leukemia (CLL), high...

Speaker: Kerry Rogers, Institution: Ohio State University, Event: SOHO 2024, Format: Interview, Subject: Leukemia, Subject: Chronic Lymphocytic Leukemia, Field: Treatment, Field: Immuno-Oncology, Field: Perspectives, Medicines: BTK inhibitors, Medicines: Ibrutinib, Medicines: Venetoclax, Medicines: Obinutuzumab, Medicines: Antibodies, Trial: RESONATE-2, fixed-duration therapy, continuous therapy, PFS, NCT01722487, NCT01724346, disease burden, continuous BTKi, CLL
#############################